Evidence map›Paper›PMID 28917628›Full record

ArticleCytotherapy2017

An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Amy Singleton, Danika Khong, Ling-Yee Chin, Shilpaa Mukundan, Matthew Li, Biju Parekkadan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Amy SingletonCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA.
Danika KhongCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA.
Ling-Yee ChinCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA.
Shilpaa MukundanCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA.
Matthew LiCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA.
Biju ParekkadanCenter for Engineering in Medicine and Surgical Services, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Shriners Hospitals for Children, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA; Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA. Electronic address: biju_parekkadan@hms.harvard.edu.
Harvard University · USMassachusetts General Hospital · USShriners Hospitals for Children - Boston · US

Funding

Artificial, Humanized Stem Cell NichesR01EB012521 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI PAREKKADAN, BIJU · 2011 to 2021
$6.0M
Organ Design and Engineering Training Program (ODET Program)T32EB016652 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2014 to 2023
$3.5M
NIBIB NIH HHS R01 EB012521NIBIB NIH HHS T32 EB016652
6 · The paper itself

Abstract

BACKGROUND

aimsCell transplants offer a new opportunity to deliver therapies with novel and complex mechanisms of action. Understanding the pharmacology of cell transplants is important to deliver this new therapy effectively. Currently, however, there are limited techniques to easily track cells after intravenous administration due to the dispersion of the graft throughout the entire body.

methodsWe herein developed an engineered cell system that secretes a luciferase enzyme to sensitively detect cell transplants independent of their locale by a simple blood test. We specifically studied a unique feature of cell transplant pharmacology-namely, immune clearance-using mesenchymal stromal cells (MSCs) as a proof-of-concept cell therapy. MSCs are a clinically relevant cell therapy that has been explored in several disease indications due to their innate properties of altering an immune response.

resultsUsing this engineered reporter, we observed specific sensitivity of cell therapy exposure to the preparation of cells, cytolysis of MSCs in an allogeneic setting and a NK cell-mediated destruction of MSCs in an autologous setting.

conclusionsOur cellular tracking method has broader implications at large for assessing in vivo kinetics of various other cell therapies.

Indexed as

AnimalsBiomarkersCell- and Tissue-Based TherapyFemaleGenetic EngineeringGreen Fluorescent ProteinsHumansKiller Cells, NaturalLuciferasesLuminescent MeasurementsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMice, Inbred BALB CMice, Inbred C57BLRecombinant ProteinsTransplantation, HomologousBiomarkersGreen Fluorescent ProteinsLuciferasesRecombinant Proteinsengineered MSCsimmune clearanceimmunogenicityluciferaseMSCNK cell

Identifiers

PMID28917628
PMCPMC5723229
OpenAlexW2755173344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.